Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug-Reference-Cited by-同舟云学术

Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug

Published:1994-01 Issue:5 Volume:13 Page:197-201
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Akamatsu T.,Matsubara T.,Saegusa Y.,Mizuno K.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/BF00390267.pdf

Reference20 articles.

1. Kashiwazaki S, Shiokawa Y (1987) Bucillamine: a new immunomodulator. Int J Immunother 3:1?6

2. Matsubara T, Saura R, Hirohata K, Ziff M (1989) Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by d-penicillamine. J Clin Invest 83:158?167

3. Matsubara T, Hirohata K (1988) Suppression of human fibroblast proliferation by d-penicillamine and copper sulfate in vitro. Arthritis Rheum 31:964?972

4. Lipsky PE, Ziff M (1978) The effect of d-penicillamine on mitogen-induced human lymphocyte proliferation: synergistic inhibition by d-penicillamine and copper salts. J Immunol 120:1006?1013

5. Lipsky PE, Ziff M (1980) Inhibition of human helper T cell function in vitro by d-penicillamine and CuSO4. J Clin Invest 65:1069?1076

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert opinion on emerging urate-lowering therapies;Expert Opinion on Emerging Drugs;2018-07-03

2. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study;Modern Rheumatology;2005-10

3. Inhibitory effect of bucillamine on laser-induced choroidal neovascularization in rats;Current Eye Research;2002-01

4. Inhibitory effects of bucillamine on increased blood-retinal barrier permeability in streptozotocin-induced diabetic rats;Current Eye Research;2002-01

5. Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, d-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric oxide by murine macrophages;International Immunopharmacology;2001-05